171 related articles for article (PubMed ID: 29033841)
1. Pharmacodynamic Evaluation and PK/PD-Based Dose Prediction of Tulathromycin: A Potential New Indication for
Zhou YF; Peng HM; Bu MX; Liu YH; Sun J; Liao XP
Front Pharmacol; 2017; 8():684. PubMed ID: 29033841
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic modeling of tylosin against Streptococcus suis in pigs.
Huang L; Zhang H; Li M; Ahmad I; Wang Y; Yuan Z
BMC Vet Res; 2018 Oct; 14(1):319. PubMed ID: 30355326
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against
Zhou Q; Zhang G; Wang Q; Liu W; Huang Y; Yu P; Li Y; Ding H; Fang B
Front Pharmacol; 2017; 8():392. PubMed ID: 28701951
[TBL] [Abstract][Full Text] [Related]
4.
Guo LL; Gao RY; Wang LH; Lin SJ; Fang BH; Zhao YD
Front Vet Sci; 2021; 8():715887. PubMed ID: 34869712
[TBL] [Abstract][Full Text] [Related]
5. Formulation of a rational dosage regimen of ceftiofur hydrochloride oily suspension by pharmacokinetic-pharmacodynamic (PK-PD) model for treatment of swine
Luo W; Wang D; Qin H; Chen D; Pan Y; Qu W; Huang L; Xie S
J Vet Sci; 2021 Nov; 22(6):e41. PubMed ID: 34854264
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic Target Assessment and PK/PD Cutoff Determination for Gamithromycin Against
Wang RL; Liu P; Chen XF; Yao X; Liao XP; Liu YH; Sun J; Zhou YF
Front Vet Sci; 2022; 9():945632. PubMed ID: 35898553
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.
Zhao Y; Guo LL; Fang B; Liu B
PLoS One; 2018; 13(12):e0209177. PubMed ID: 30596709
[TBL] [Abstract][Full Text] [Related]
8. PK-PD Integration Modeling and Cutoff Value of Florfenicol against
Lei Z; Liu Q; Yang S; Yang B; Khaliq H; Li K; Ahmed S; Sajid A; Zhang B; Chen P; Qiu Y; Cao J; He Q
Front Pharmacol; 2018; 9():2. PubMed ID: 29387013
[TBL] [Abstract][Full Text] [Related]
9. Standard PK/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calf.
Toutain PL; Potter T; Pelligand L; Lacroix M; Illambas J; Lees P
J Vet Pharmacol Ther; 2017 Jan; 40(1):16-27. PubMed ID: 27501187
[TBL] [Abstract][Full Text] [Related]
10. PK-PD Modeling and Optimal Dosing Regimen of Acetylkitasamycin against
Huang A; Mao F; Huang L; Xie S; Pan Y; Qu W; Cheng G; Liu Z; Yuan Z; Peng D; Hao H
Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203885
[No Abstract] [Full Text] [Related]
11. Pharmacokinetic/Pharmacodynamic Relationships of Tulathromycin Against
Yao L; Yang L; Ling Y; Wei Y; Shen X; Ding H
Front Vet Sci; 2022; 9():822432. PubMed ID: 35419449
[TBL] [Abstract][Full Text] [Related]
12. PK-PD Analysis of Marbofloxacin against
Lei Z; Liu Q; Yang B; Khaliq H; Cao J; He Q
Front Pharmacol; 2017; 8():856. PubMed ID: 29209222
[TBL] [Abstract][Full Text] [Related]
13. Synovial and Systemic Pharmacokinetics of Florfenicol and PK/PD Integration against
Somogyi Z; Mag P; Kovács D; Kerek Á; Szabó P; Makrai L; Jerzsele Á
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057005
[TBL] [Abstract][Full Text] [Related]
14. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
Andes D; Craig WA
Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers.
Sang K; Hao H; Huang L; Wang X; Yuan Z
Front Vet Sci; 2015; 2():80. PubMed ID: 26779495
[TBL] [Abstract][Full Text] [Related]
17. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
Lepak AJ; Andes DR
Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
[TBL] [Abstract][Full Text] [Related]
18. Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
Blondeau JM; Fitch SD
PLoS One; 2019; 14(1):e0210154. PubMed ID: 30629633
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic integration of danofloxacin in the calf.
Shojaee Aliabadi F; Lees P
Res Vet Sci; 2003 Jun; 74(3):247-59. PubMed ID: 12726744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
